26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER's Satellite Symposia at MHS
August 1-2, 2025
Register Now!
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
8th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Adverse Event Management and Treatment Response Assessment
July 21st 2025Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos for accurate evaluation, and how treatment effectiveness is monitored through carefully timed blood tests, imaging, and bone marrow biopsies—including minimal residual disease testing—to balance thorough assessment with minimizing patient discomfort.
Patient Perspective: Navigating Multiple Myeloma Treatment
July 21st 2025Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge 4-drug regimens, clear communication, and shared decision-making—can empower them, ease anxiety, and support long-term remission and quality of life.
Case Study: Sarah’s Journey with High-Burden BRAF V600E Melanoma
July 18th 2025This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.
Translating RELATIVITY-020 Part E Dosing Insights to Clinical Practice
July 18th 2025Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable responses, insights from the RELATIVITY-020 trial supporting standard-dose relatlimab due to its safety and efficacy balance, and emerging LAG-3 agents such as fianlimab that may influence future therapeutic strategies.
The Multidisciplinary Approach to Care for Advanced NSCLC
July 17th 2025Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying mechanisms (hypoalbuminemia) and may benefit from albumin infusion, dose holds, or consultation with specialists for severe cases such as infected scalp wounds.
Managing Dermatologic AEs With Amivantamab/Lazertinib: Updates From the COCOON Clinical Trial
July 17th 2025Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and topical treatments, can reduce skin toxicities by 50% in patients receiving amivantamab plus lazertinib therapy.
Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma
July 16th 2025Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated patients and emphasizing the importance of managing unique keratin-related and neurologic toxicities linked to GPRC5D expression.
Treatment Initiation and Supportive Care Processes
July 14th 2025Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the four-drug regimen, logistics, and supportive care to empower patients and ensure safety throughout their treatment journey.